FIELD: medicine.
SUBSTANCE: immunogenic product comprising IFNα coupled to a molecule of keyhole limpet hemocyanin (KLH), is used in therapeutically effective amount that is administered to a specified subject in one introduction which is more than 30 micrograms, and the ratio of IFNα to KLH by weight is from 0.06 to 0.6. The group of inventions also refers to a unit dosage drug form containing more than 30 μg of immunogenic product, as well as a kit for treating IFN-associatedα state of the subject in need thereof.
EFFECT: neutralisation of IFNα in vivo, when more than 30 μg of the immunogenic product is used, increase of the production of IFN-binding antibodies in patients in response to the above immunogenic product.
15 cl, 11 ex, 8 tbl, 5 dwg
| Title | Year | Author | Number |
|---|---|---|---|
| IMMUNOGENIC PRODUCT CONTAINING IL-4 AND/OR IL-13 FOR TREATMENT OF DISORDERS ASSOCIATED WITH ABERRANT EXPRESSION OR ACTIVITY OF IL-4 AND/OR IL-13 | 2019 |
|
RU2809548C2 |
| COMPOSITIONS OF PEPTIDE CONJUGATE AND METHODS FOR PREVENTION AND TREATMENT OF ALZHEIMER'S DISEASE | 2006 |
|
RU2406529C2 |
| INTERFERON ALPHA 1 RECEPTOR ANTIBODIES AND USE THEREOF | 2005 |
|
RU2600884C2 |
| HYBRID PEPTIDE CARRYING PROTEINS AS VACCINES AGAINST ALLERGY | 2012 |
|
RU2630652C2 |
| ANTIBODIES OF INTERFERON ALFA RECEPTOR 1 AND THEIR APPLICATION | 2005 |
|
RU2412202C2 |
| ANTI-IFNAR1 ANTIBODIES WITH LOWER LIGAND Fc AFFINITY | 2009 |
|
RU2556125C2 |
| COMPOSITIONS OF CARBOHYDRATE VACCINE FOR INDUCING IMMUNE RESPONSES AND USES THEREOF IN CANCER TREATMENT | 2014 |
|
RU2666141C2 |
| COMPOSITION FOR STIMULATION AND ENHANCEMENT OF PRODUCTION OF ANTIBODY THAT RECOGNIZE GANGLIOSIDE | 1994 |
|
RU2174013C2 |
| CONJUGATES FOR ADMINISTERING BIOLOGICALLY ACTIVE COMPOUNDS | 2009 |
|
RU2567667C2 |
| MONOCLONAL ANTIBODIES AGAINST INTERFERON-ALPHA AND APPLICATION METHODS | 2006 |
|
RU2431638C2 |
